Chemomab Therapeutics (NASDAQ:CMMB) Upgraded at Oppenheimer

Chemomab Therapeutics (NASDAQ:CMMB) was upgraded by Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Monday, Marketbeat Ratings reports. The firm currently has a $6.00 price objective on the stock.

Chemomab Therapeutics Stock Performance

NASDAQ CMMB opened at $0.74 on Monday. Chemomab Therapeutics has a one year low of $0.42 and a one year high of $1.89. The company’s 50 day moving average price is $0.74 and its 200 day moving average price is $0.64. The firm has a market capitalization of $8.18 million, a price-to-earnings ratio of -0.35 and a beta of 0.39.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.14. During the same quarter in the previous year, the business posted ($0.72) earnings per share. Sell-side analysts forecast that Chemomab Therapeutics will post -1.2 EPS for the current fiscal year.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).